http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
-
Moderna (MRNA) and Merck (MRK) Announce mRNA-4157 in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Pat
-
Financial Literacy for All Welcomes American Express, Dow Jones, and Moderna to its Mission of Advancing Financial Literacy
-
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
-
Moderna (MRNA) and Merck (MRK) Report MRNA-4157/V940 in Combination With Keytruda Received Prime Scheme Designation in EU
-
Gandeeva and Moderna Enter into Cryo-EM Research Collaboration to Explore Protein Surface Structure at Atomic Resolution
-
Moderna (MRNA) And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
-
Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
-
Personalis (PSNL), Moderna (MRNA) Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
-
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
-
Moderna (MRNA) and CytomX (CTMX) Enter Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
-
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
-
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
-
Tesla, Moderna, Mesa Air rise premarket; Meta Platforms lower
-
Senda Biosciences Announces Close of $123 Million Series C Financing
-
Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)
-
Moderna files for U.S. authorization of COVID shot for kids under 6
-
Alnylam Pharma (ALNY) Files Patent Infringement Suits against Pfizer (PFE) and Moderna (MRNA)
-
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT
-
Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology
-
Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies
-
'Tidal wave': Omicron could put U.S. COVID-19 surge into overdrive
-
Pre-Open Stock Movers 11/29: (KRYS) (ADGI) (TWTR) Higher; (MRK) (UPS) Lower (more...)
-
Pre-Open Stock Movers 10/22: (PHUN) (DWAC) (MAT) Higher; (MTCR) (SNAP) (INTC) Lower (more...)
-
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
-
Data suggests mRNA booster dose generates stronger antibody response after J&J shot - Axios
-
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platform
-
U.S. authorizes third shot of COVID-19 vaccines for the immunocompromised
-
Qatar re-opens for fully vaccinated international travellers
-
Baxter BioPharma Solutions (BAX) and Moderna (MRNA) Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.
-
Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.
-
FDA Advisory Committee to Meet Dec. 17 on Moderna (MRNA) EAU for its COVID-19 Vaccine
-
Exclusive: EU eyes COVID vaccine deal with Moderna at less than $25 per dose, says source
-
U.S. FDA safety guidelines likely to push COVID-19 vaccine authorization past election
-
Vaccine makers announce pledge, outlining united commitment to uphold integrity of scientific process
-
Biopharma Leaders Unite to Stand With Science
-
Biopharma Leaders Unite to Stand with Science
-
Biopharma Leaders Unite To Stand With Science
-
Biopharma Leaders Unite to Stand with Science
-
Biopharma Leaders Unite to Stand with Science
-
Indigo Ag Announces an Additional $360M in Financing, Appoints Stéphane Bancel, Moderna CEO, to Board of Directors
-
Moderna, Inc. (MRNA) to Join the NASDAQ-100 Index Beginning July 20
-
Moderna, Inc. to Join the NASDAQ-100 Index Beginning July 20, 2020
-
Moderna (MRNA) coronavirus vaccine tester fainted, had high fever during trial - NY Post
-
Vaccine not only for rich, Cuomo says, and decries leadership by tweet
-
Moderna (MRNA) and Lonza Announce Worldwide Pact to Manufacture Moderna’s Vaccine Against Novel Coronavirus
-
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
-
German coronavirus vaccine developer CureVac denies any U.S. bid
-
Moderna Named Top Employer by Science for Fifth Consecutive Year
-
Moderna (MRNA) Reports Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at ASCO 2019 Meetings

